The english version of the website of the School of Medicine is under development


Combined Interactions with I-, I-Imidazoline Binding Sites and α-Adrenoceptors To Manage Opioid Addiction.

TitleCombined Interactions with I-, I-Imidazoline Binding Sites and α-Adrenoceptors To Manage Opioid Addiction.
Publication TypeJournal Article
Year of Publication2016
AuthorsGiusepponi, M. Elena, Cifani C., Di Bonaventura M. Vittoria M., Mattioli L., Hudson A., Diamanti E., Del Bello F., Giannella M., Mammoli V., Paoletti C. Dalila, Piergentili A., Pigini M., & Quaglia W.
JournalACS Med Chem Lett
Date Published2016 Oct 13

Tolerance and dependence associated with chronic opioid exposure result from molecular, cellular, and neural network adaptations. Such adaptations concern opioid and nonopioid systems, including α-adrenoceptors (α-ARs) and I- and I-imidazoline binding sites (IBS). Agmatine, one of the hypothesized endogenous ligands of IBS, targeting several systems including α-ARs and IBS, proved to be able to regulate opioid-induced analgesia and to attenuate the development of tolerance and dependence. Interested in the complex pharmacological profile of agmatine and considering the nature of its targets, we evaluated two series of imidazolines, rationally designed to simultaneously interact with I-/I-IBS or I-/I-IBS/α-ARs. The compounds showing the highest affinities for I-/I-IBS or I-/I-IBS/α-ARs have been selected for their evaluation on opiate withdrawal syndrome. Interestingly, , displaying I-/I-IBS/α-ARs interaction profile, appears more effective in reducing expression and acquisition of morphine dependence and, therefore, might be considered a promising tool in managing opioid addiction.

Alternate JournalACS Med Chem Lett
PubMed ID27774136
PubMed Central IDPMC5066154


Secretariat of the School of Medicine


Schoole of Medicince presence in social networks
Follow Us or Connect with us.